Ceva Sante Animale S.A. – Trademark Portfolio

Entity Type: 99

Ceva Sante Animale S.A. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include CEVAC and ULTIFEND. The owner is based in Libourne.

10 avenue de la Ballastière

Libourne 33500 , FR

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ULTIFEND
ULTIFEND
Registered 2018
FELITUDE
FELITUDE
Abandoned 2012
FELITUDE
FELITUDE
Abandoned 2009
CEVAC
CEVAC
Registered 2008
F3
F3
Abandoned 2007
CEVAMUNE
CEVAMUNE
Cancelled 2005
REPROKIT
REPROKIT
Cancelled 2004

Trademark Classifications

Ceva Sante Animale S.A.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (8 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ceva Sante Animale S.A. have?

Ceva Sante Animale S.A. has 8 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned, 2 cancelled.

What trademark classes does Ceva Sante Animale S.A. file in?

Ceva Sante Animale S.A. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Ceva Sante Animale S.A.'s most well-known trademarks?

Ceva Sante Animale S.A.'s registered trademark portfolio includes well-known marks such as CEVAC and ULTIFEND. These are among 2 currently registered trademarks in the portfolio.

What is Ceva Sante Animale S.A.'s trademark registration success rate?

Ceva Sante Animale S.A. has a 25% trademark registration rate, with 2 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.